Observational studyJournal of hematology & oncology2017

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).

Michael Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.